AZN LUPUS SETBACK SHIFTS FOCUS TO J15 Sep 2018 19:26
From 3 september from quoted data
Only a handful of companies are known to have similar TYK2 or TYK2/JAK-1 inhibitors in development: Pfizer’s PF-06700841 is next by virtue of mid stage studies for psoriasis, Crohn’s and ulcerative colitis. Two others are in preclinical development – one by the private US company, Nimbus Therapeutics, the other by LSE-listed biotech, Sareum (SAR), which is understood to be considering a development strategy that may include SLE and/or lupus nephritis. Marten & Co has identified Sareum as having potential for a stock re-rating based on improving understanding of the TYK2 class.